Tag: #biotech

Articles related to biotech

markets

Pfizer Raises 2026 Guidance After Stronger Third Quarter, Names New CFO

Pfizer raised its 2026 revenue and EPS outlook after stronger Q3 results led by non‑COVID drugs; Paxlovid and Comirnaty sales fell while new CFO was named.

$PFE, #pfizer, #pharma, #earnings, #biotech

industry

Ultragenyx Agrees to Sell FDA Rare Pediatric-Disease Priority Review Voucher for $203 Million

Ultragenyx said it agreed to sell a rare pediatric disease priority review voucher tied to gene therapy FAYUVI for $203M, its second PRV sale this month.

$RARE, #biotech, #ultragenyx, #prv, #raredisease

industry

Amgen discloses material cybersecurity incident after data exfiltration from third‑party cloud environments

Amgen disclosed a material cybersecurity incident in a July SEC filing, saying unauthorized activity in third‑party cloud environments led to exfiltration of proprietary and patient data.

$AMGN, #amgen, #cybersecurity, #biotech, #sec

health

Deramiocel improves arm function and cardiac measures in phase 3 trial as FDA advisory panel reviews Capricor's application

Phase 3 trial of deramiocel (CAP-1002) showed significant benefits on upper-limb function and cardiac measures; FDA advisory panel is reviewing the data.

$CAPR, #duchenne, #muscular-dystrophy, #biotech, #fda

health

Intellia’s one-time CRISPR therapy cuts hereditary angioedema attacks 87% in Phase 3; rolling FDA filing started

Phase 3 trial of Intellia's one-time in‑vivo CRISPR therapy lonvo‑z cut hereditary angioedema attacks 87%; company began rolling FDA filing.

$NTLA, #crispr, #geneediting, #biotech, #hereditaryangioedema, #intellia

industry

Neurocrine to Buy Soleno for $2.9 Billion, Picks Up Prader‑Willi Drug VYKAT XR

Neurocrine will acquire Soleno for $2.9B to add VYKAT XR, the newly approved Prader‑Willi hyperphagia drug, aiming to expand its rare‑disease portfolio.

#biotech, #m&a, #raredisease